# Marqeta, Inc.: financial statements, quarterly

MQ · Nasdaq · CIK 1522540 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mq.md) · [Financials](/companies/mq/financials.md) · [Filings](/companies/mq/filings.md) · [Insiders](/companies/mq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [109](/filings/0001628280-24-045055.md) | [119 d](/filings/0001522540-26-000017.md) | [118](/filings/0001628280-25-023249.md) | [125](/filings/0001522540-25-000022.md) | [128](/filings/0001522540-25-000035.md) | [136 d](/filings/0001522540-26-000017.md) | [139](/filings/0001522540-26-000038.md) | [150](/filings/0001522540-26-000063.md) | [163](/filings/0001522540-25-000035.md) | [172 d](/filings/0001522540-26-000017.md) | [166](/filings/0001522540-26-000038.md) | [176](/filings/0001522540-26-000063.md) |
| Cost of revenue | $m | [36.4](/filings/0001628280-24-045055.md) | [35.6 d](/filings/0001522540-26-000017.md) | [33.8](/filings/0001628280-25-023249.md) | [45.9](/filings/0001522540-25-000022.md) | [37.8](/filings/0001522540-25-000035.md) | [37.6 d](/filings/0001522540-26-000017.md) | [40.4](/filings/0001522540-26-000038.md) | [46.3](/filings/0001522540-26-000063.md) | [48.7](/filings/0001522540-25-000035.md) | [52.1 d](/filings/0001522540-26-000017.md) | [48.2](/filings/0001522540-26-000038.md) | [54.1](/filings/0001522540-26-000063.md) |
| Gross profit | $m | [72.5](/filings/0001628280-24-045055.md) | [83.2 d](/filings/0001522540-26-000017.md) | [84.2](/filings/0001628280-25-023249.md) | [79.4](/filings/0001522540-25-000022.md) | [90.1](/filings/0001522540-25-000035.md) | [98.2 d](/filings/0001522540-26-000017.md) | [98.7](/filings/0001522540-26-000038.md) | [104](/filings/0001522540-26-000063.md) | [115](/filings/0001522540-25-000035.md) | [120 d](/filings/0001522540-26-000017.md) | [118](/filings/0001522540-26-000038.md) | [122](/filings/0001522540-26-000063.md) |
| Operating income | $m | [(69.8)](/filings/0001628280-24-045055.md) | [(56.3) d](/filings/0001522540-26-000017.md) | [(49.9)](/filings/0001628280-25-023249.md) | [105](/filings/0001522540-25-000022.md) | [(42.2)](/filings/0001522540-25-000035.md) | [(37.4) d](/filings/0001522540-26-000017.md) | [(18.5)](/filings/0001522540-26-000038.md) | [(9.2)](/filings/0001522540-26-000063.md) | [(10.4)](/filings/0001522540-25-000035.md) | [(8.3) d](/filings/0001522540-26-000017.md) | [2.1](/filings/0001522540-26-000038.md) | [3.6](/filings/0001522540-26-000063.md) |
| Income tax | $m | [0.2](/filings/0001628280-24-045055.md) | [(1.0) d](/filings/0001522540-26-000017.md) | [0.1](/filings/0001628280-25-023249.md) | [0.2](/filings/0001522540-25-000022.md) | [0.1](/filings/0001522540-25-000035.md) | [0.4 d](/filings/0001522540-26-000017.md) | [0.2](/filings/0001522540-26-000038.md) | [0.2](/filings/0001522540-26-000063.md) | [0.5](/filings/0001522540-25-000035.md) | [(0.3) d](/filings/0001522540-26-000017.md) | [0.2](/filings/0001522540-26-000038.md) | [0.5](/filings/0001522540-26-000063.md) |
| Net income | $m | [(55.0)](/filings/0001628280-24-045055.md) | [(40.4) d](/filings/0001522540-26-000017.md) | [(36.1)](/filings/0001522540-25-000035.md) | [119](/filings/0001522540-25-000035.md) | [(28.6)](/filings/0001522540-25-000035.md) | [(27.1) d](/filings/0001522540-26-000017.md) | [(8.3)](/filings/0001522540-26-000063.md) | [(0.6)](/filings/0001522540-26-000063.md) | [(3.6)](/filings/0001522540-25-000035.md) | [(1.4) d](/filings/0001522540-26-000017.md) | [7.8](/filings/0001522540-26-000063.md) | [7.6](/filings/0001522540-26-000063.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [948](/filings/0001628280-24-045055.md) | [981](/filings/0001522540-26-000017.md) | [970](/filings/0001628280-25-023249.md) | [925](/filings/0001522540-25-000022.md) | [886](/filings/0001522540-25-000035.md) | [923](/filings/0001522540-26-000017.md) | [831](/filings/0001522540-26-000038.md) | [733](/filings/0001522540-26-000063.md) | [747](/filings/0001522540-25-000035.md) | [709](/filings/0001522540-26-000063.md) | [675](/filings/0001522540-26-000038.md) | [691](/filings/0001522540-26-000063.md) |
| Current assets | $m | [1,407](/filings/0001628280-23-037578.md) | [1,389](/filings/0001628280-25-008232.md) | [1,348](/filings/0001628280-24-021181.md) | [1,273](/filings/0001628280-24-035709.md) | [1,221](/filings/0001628280-24-045055.md) | [1,249](/filings/0001522540-26-000017.md) | [1,135](/filings/0001628280-25-023249.md) | [990](/filings/0001522540-25-000022.md) | [1,200](/filings/0001522540-25-000035.md) | [1,235](/filings/0001522540-26-000063.md) | [1,188](/filings/0001522540-26-000038.md) | [1,102](/filings/0001522540-26-000063.md) |
| Total assets | $m | [1,603](/filings/0001628280-23-037578.md) | [1,590](/filings/0001628280-25-008232.md) | [1,558](/filings/0001628280-24-021181.md) | [1,488](/filings/0001628280-24-035709.md) | [1,436](/filings/0001628280-24-045055.md) | [1,463](/filings/0001522540-26-000017.md) | [1,350](/filings/0001628280-25-023249.md) | [1,215](/filings/0001522540-25-000022.md) | [1,488](/filings/0001522540-25-000035.md) | [1,525](/filings/0001522540-26-000063.md) | [1,477](/filings/0001522540-26-000038.md) | [1,392](/filings/0001522540-26-000063.md) |
| Current liabilities | $m | [297](/filings/0001628280-23-037578.md) | [337](/filings/0001628280-25-008232.md) | [339](/filings/0001628280-24-021181.md) | [338](/filings/0001628280-24-035709.md) | [334](/filings/0001628280-24-045055.md) | [371](/filings/0001522540-26-000017.md) | [357](/filings/0001628280-25-023249.md) | [361](/filings/0001522540-25-000022.md) | [637](/filings/0001522540-25-000035.md) | [749](/filings/0001522540-26-000063.md) | [721](/filings/0001522540-26-000038.md) | [662](/filings/0001522540-26-000063.md) |
| Total liabilities | $m | [308](/filings/0001628280-23-037578.md) | [346](/filings/0001628280-25-008232.md) | [348](/filings/0001628280-24-021181.md) | [346](/filings/0001628280-24-035709.md) | [340](/filings/0001628280-24-045055.md) | [378](/filings/0001522540-26-000017.md) | [362](/filings/0001628280-25-023249.md) | [371](/filings/0001522540-25-000022.md) | [649](/filings/0001522540-25-000035.md) | [763](/filings/0001522540-26-000063.md) | [734](/filings/0001522540-26-000038.md) | [677](/filings/0001522540-26-000063.md) |
| Shareholders' equity | $m | [1,295](/filings/0001628280-24-045055.md) | [1,243](/filings/0001522540-26-000017.md) | [1,211](/filings/0001522540-25-000035.md) | [1,142](/filings/0001522540-25-000035.md) | [1,096](/filings/0001522540-25-000035.md) | [1,085](/filings/0001522540-26-000063.md) | [987](/filings/0001522540-26-000063.md) | [843](/filings/0001522540-26-000063.md) | [839](/filings/0001522540-25-000035.md) | [762](/filings/0001522540-26-000063.md) | [742](/filings/0001522540-26-000063.md) | [716](/filings/0001522540-26-000063.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [41.1 d](/filings/0001628280-24-045055.md) | [16.5 d](/filings/0001522540-26-000017.md) | [0.4](/filings/0001628280-25-023249.md) | [25.7 d](/filings/0001522540-25-000022.md) | [7.3 d](/filings/0001522540-25-000035.md) | [24.8 d](/filings/0001522540-26-000017.md) | [10.0](/filings/0001522540-26-000038.md) | [12.5 d](/filings/0001522540-26-000063.md) | [86.8 d](/filings/0001522540-25-000035.md) | [53.3 d](/filings/0001522540-26-000017.md) | [(3.4)](/filings/0001522540-26-000038.md) | [63.2 d](/filings/0001522540-26-000063.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001628280-24-045055.md) | [0.0 d](/filings/0001522540-26-000017.md) | [1.2](/filings/0001628280-25-023249.md) | [1.0 d](/filings/0001522540-25-000022.md) | [0.2 d](/filings/0001522540-25-000035.md) | [0.0 d](/filings/0001522540-26-000017.md) | [1.3](/filings/0001522540-26-000038.md) | [0.3 d](/filings/0001522540-26-000063.md) | [0.4 d](/filings/0001522540-25-000035.md) | [(0.2) d](/filings/0001522540-26-000017.md) | [1.3](/filings/0001522540-26-000038.md) | [0.2 d](/filings/0001522540-26-000063.md) |
| Share repurchases | $m | [64.4 d](/filings/0001628280-24-045055.md) | [58.9 d](/filings/0001522540-26-000017.md) | [33.7](/filings/0001628280-25-023249.md) | [57.5 d](/filings/0001522540-25-000022.md) | [46.6 d](/filings/0001522540-25-000035.md) | [16.7 d](/filings/0001522540-26-000017.md) | [111](/filings/0001522540-26-000038.md) | [164 d](/filings/0001522540-26-000063.md) | [19.6 d](/filings/0001522540-25-000035.md) | [96.6 d](/filings/0001522540-26-000017.md) | [39.2](/filings/0001522540-26-000038.md) | [54.7 d](/filings/0001522540-26-000063.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [549](/filings/0001628280-23-037578.md) | [540](/filings/0001628280-24-021181.md) | [538](/filings/0001628280-24-035709.md) | [529](/filings/0001628280-24-045055.md) | [518](/filings/0001628280-25-023249.md) | [524](/filings/0001522540-25-000022.md) | [507](/filings/0001522540-25-000035.md) | [501](/filings/0001522540-26-000038.md) | [115](/filings/0001522540-26-000063.md) | [449](/filings/0001522540-25-000035.md) | [434](/filings/0001522540-26-000038.md) | [107](/filings/0001522540-26-000063.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.